JANXJANXHealthcare · Biotechnology

JANX Stock Forecast: Janux Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 11 Nov 2026
$12
+2.57% on the day

The 18 Wall Street analysts covering Janux Therapeutics, Inc. hold a median 12-month price target of $28 — +126.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 70 of 100 as at 11 Nov 2026 — in the upper half. Here, the model and the Street point the same way.

Market cap
$780.7M
Ticker Nerd rank
70/ 100
Median analyst target
$28
Analysts covering
18
Revenue$10.3M
Operating income−$31.7M
Net income−$22.0M
Free cash flow$12.3M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−32.1%
1M
−32.8%
YTD
−10.5%
1Y
−57.2%
From 52W high
−64.5%
From 52W low
+2.6%
$12
$35
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

JANX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Janux Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 11 Nov 2026
70/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
92
Quality
89
Accruals
74
Revisions
64
Issuance
54
Size
48
Value
37
Volatility
31
Momentum
28

Growth (92): Sales and profits are climbing, and climbing faster than before.

Momentum (28): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

JANX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on JANX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$20$30$40$50$60Jan 26Apr 26Jul 26Oct 26JANXHigh $60Median $28Low $15

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says18 analysts
16 Buy1 Hold1 Sell
Low $15Median $28High $60

The green dot is the last close — the median target sits +126.7% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 3 moved their price target up and 2 moved it down.

DateFirmActionRatingTarget
6 Nov 2026BarclaysMaintainsUnderweight$14 → $15
6 Nov 2026Truist SecuritiesMaintainsBuy$26 → $27
6 Nov 2026WedbushMaintainsOutperform$36 → $40
24 Aug 2026Wolfe ResearchUpgradeOutperform—
24 Aug 2026Wolfe ResearchUpgradeOutperform$23
7 Aug 2026GuggenheimMaintainsBuy—
7 Aug 2026GuggenheimMaintainsBuy$58 → $55
25 June 2026Truist SecuritiesAssumesBuy$80 → $26
8 May 2026GuggenheimMaintainsBuy—
8 May 2026Piper SandlerMaintainsOverweight—
8 May 2026WedbushMaintainsOutperform—
28 Apr 2026Jones TradingMaintainsBuy—
20 Apr 2026BarclaysDowngradeUnderweight—
15 Apr 2026UBSDowngradeNeutral—
27 Feb 2026Cantor FitzgeraldMaintainsOverweight—
27 Feb 2026GuggenheimMaintainsBuy—
20 Jan 2026Clear StreetDowngradeHold—
16 Jan 2026Piper SandlerMaintainsOverweight—
17 Dec 2025BarclaysMaintainsOverweight—
2 Dec 2025B of A SecuritiesMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

JANX appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time.

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

JANX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Nov 2026, Janux Therapeutics, Inc. returned −57.2% against +12.4% for the S&P 500, dividends included.

JANX vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120Jan 26Apr 26Jul 26Oct 26JANXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

JANX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
7
Analysts cutting
5
Fundamentals

Janux Therapeutics, Inc. (JANX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−6.7×

Cheaper than 92% of US stocks

Price / sales
30.9×

Cheaper than 6% of US stocks

Price / book
0.8×

Cheaper than 76% of US stocks

EV / EBITDA
1.1×

Cheaper than 58% of US stocks

Growth & margins
Revenue growth (YoY)
−7.1%

Higher than 19% of US stocks

Earnings growth (YoY)
—
Gross margin
—
Operating margin
−336.5%

Higher than 8% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−10.6%

Higher than 35% of US stocks

Return on assets
−8.7%

Higher than 27% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Janux Therapeutics, Inc. (JANX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Janux Therapeutics, Inc. has a market value of $780.7M and an enterprise value of −$144.6M.

  • Revenue in the twelve months to 30 June 2026: $24.0M. The latest quarter shrank 7.1% year on year.

  • Net income over the same four quarters: −$102.6M, a −427.5% net margin.

  • Diluted earnings per share, trailing twelve months: −$1.64.

  • Free cash flow in the twelve months to 30 June 2026: −$41.9M.

  • Janux Therapeutics, Inc. spent $0.0 on share buybacks in the twelve months to 30 June 2026.

  • Shares outstanding: 61.1M.

  • Trailing P/E: −6.7×; forward P/E: −4.6× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Janux Therapeutics, Inc. employs 114 people — $211K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 10 Nov 2026

Data provided by Twelve Data

Peers

JANX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
JANXJanux Therapeutics, Inc.$780.7M70
OABIOmniAb, Inc.$741.5M100
CGEMCullinan Therapeutics, Inc.$736.9M75
IAMIambic Therapeutics, Inc.$729.3M1
ATTOAttovia Therapeutics, Inc.$762.5M4
NVCTNuvectis Pharma, Inc.$722.2M54
IMMXImmix Biopharma, Inc.$717.9M38

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Janux Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest JANX news & analysis

Janux Therapeutics, Inc. (JANX) Discusses JANX011 Phase 1 Healthy Volunteer Data and Autoimmune Development Strategy Transcript

Seeking Alpha · 9 Nov 2026neutral

Janux Therapeutics held a conference call discussing Phase 1 healthy-volunteer data for JANX011 and its autoimmune development strategy. The provided excerpt contains the call title and participant information but no details about the data or strategy.

Why it matters — The call concerns JANX011’s early clinical data and the company’s autoimmune development plans, though the excerpt gives no further substance to assess.

Janux Therapeutics Announces Positive Initial Phase 1 Data for JANX011 in Healthy Volunteers, Supporting Planned Development in Patients with Autoimmune Disease

Business Wire · 9 Nov 2026positive

Janux Therapeutics announced initial Phase 1 results for JANX011 in healthy volunteers and outlined planned clinical development in autoimmune diseases. JANX011 is the first program from the company’s ARM platform to enter clinical development.

Why it matters — The announcement provides an update on JANX011’s early clinical progress and Janux’s planned development strategy in autoimmune disease.

Janux Therapeutics, Inc. (JANX) Reports Q3 Loss, Beats Revenue Estimates

Zacks Investment Research · 5 Nov 2026positive

Janux Therapeutics reported a quarterly loss of $0.34 per share, compared with the Zacks Consensus Estimate of a $0.45 loss and a $0.39 loss per share a year earlier.

Why it matters — The per-share loss was smaller than the consensus estimate and the loss reported a year ago, providing an update on JANX’s quarterly results.

Janux Therapeutics Reports Third Quarter 2026 Financial Results and Business Highlights

Business Wire · 5 Nov 2026positive

Janux Therapeutics reported financial results for the quarter ended September 30, 2026, and provided a business update. The company said it dosed the first patient in the Phase 1 study of JANX013 in combination with JANX007 during the quarter.

Why it matters — JANX watchers may note progress in the clinical portfolio alongside the reported quarterly results.

Janux Therapeutics to Host Virtual Event Presenting Initial Phase 1 Clinical Data for JANX011 in Healthy Volunteers

Business Wire · 2 Nov 2026neutral

Janux Therapeutics announced a virtual event on November 9, 2026, at 8:30 a.m. ET, where CEO David Campbell will present initial Phase 1 single-ascending-dose data for JANX011 in healthy volunteers. The presentation will cover safety, pharmacokinetics and pharmacodynamics.

Why it matters — JANX watchers can learn about the initial clinical data and the topics to be discussed for JANX011.

FAQ

Frequently asked questions about JANX stock

What is the JANX stock price forecast for 2026-2027?

The 18 Wall Street analysts covering Janux Therapeutics, Inc. have a median 12-month price target of $28, with estimates ranging from $15 to $60. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is JANX stock a buy right now?

Of the 18 analysts covering Janux Therapeutics, Inc., 16 rate it a Buy, 1 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Janux Therapeutics, Inc. 70 out of 100 across roughly 4,600 US stocks as at 11 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank JANX?

As at 11 Nov 2026, Janux Therapeutics, Inc. ranks 70 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (92 of 100).

Will JANX stock go up?

No one can know that. What the data says: the median 12-month target from 18 analysts implies +126.7% from the last close, and Ticker Nerd's factor model ranks Janux Therapeutics, Inc. 70 out of 100 as at 11 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the JANX stock forecast for 2030?

No analyst covering Janux Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for JANX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $15 to $60 over the next 12 months.

How has JANX stock performed over the past year?

Janux Therapeutics, Inc. returned -57.2% over the 12 months to 11 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Janux Therapeutics, Inc. do?

Janux Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing precision-engineered immunotherapies for cancer.

What is the latest news on JANX?

The most recent item we track (Seeking Alpha, 9 Nov 2026): "Janux Therapeutics, Inc. (JANX) Discusses JANX011 Phase 1 Healthy Volunteer Data and Autoimmune Development Strategy Transcript". Janux Therapeutics held a conference call discussing Phase 1 healthy-volunteer data for JANX011 and its autoimmune development strategy. The provided excerpt contains the call title and participant information but no details about the data or strategy.

Company

About Janux Therapeutics, Inc.

Janux Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing precision-engineered immunotherapies for cancer. The company’s core programs are built around its Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms, which are designed to activate immune responses selectively in tumors while limiting effects on healthy tissue. Janux Therapeutics is advancing a pipeline of investigational candidates that target a range of cancers, including solid tumors and prostate cancer, and its research also extends to autoimmune disease applications. The company works through preclinical and early clinical development activities, supported by collaboration and discovery efforts, positioning it as a platform-driven biotechnology business centered on novel immune-oncology research.

CEO Dr. David Alan Campbell Ph.D. · 114 employees · United States · https://www.januxrx.com